Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25365110 | 0.94 | MEN1 (0.48) | MEN1KMT2ADPP7CTSCCYP3A4 | |
| SCHEMBL25365122 | 0.94 | MEN1 (0.48) | MEN1KMT2ADPP7CTSCCYP3A4 | |
| SCHEMBL30456801 | 0.94 | MEN1 (0.48) | MEN1KMT2ADPP7CTSCCYP3A4 | |
| SCHEMBL25365117 | 0.94 | MEN1 (0.48) | MEN1KMT2ADPP7CTSCCYP3A4 | |
| SCHEMBL29679729 | 0.94 | MEN1 (0.41) | MEN1KMT2ADPP7CTSCCYP3A4 | |
| SCHEMBL30818043 | 0.92 | MEN1 (0.43) | MEN1KMT2ADPP7CTSCCYP3A4 | |
| SCHEMBL29876570 | 0.92 | MEN1 (0.43) | MEN1KMT2ADPP7CTSCCYP3A4 | |
| SCHEMBL30193956 | 0.92 | MEN1 (0.42) | MEN1KMT2ADPP7CTSCCYP3A4 | |
| SCHEMBL30193332 | 0.92 | MEN1 (0.42) | MEN1KMT2ADPP7CTSCCYP3A4 | |
| SCHEMBL30287605 | 0.92 | MEN1 (0.42) | MEN1KMT2ADPP7CTSCCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181173-A | Preparation method of Tirzepatide | 深圳市健元医药科技有限公司 | 2022-10-14 | — | — | CN | claimed |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-3990064-B1 | INJECTION DEVICE | SANOFI SA (FR) | 2024-10-09 | — | — | EP | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-3442624-B1 | NEEDLE ASSEMBLY AND DRUG DELIVERY DEVICE HAVING SUCH NEEDLE ASSEMBLY | SANOFI AVENTIS DEUTSCHLAND (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-20230091653-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC. | 2023-03-23 | — | — | US | disclosed |
| EP-4144362-A1 | COMPOSITIONS COMPRISING SHORT-ACTING HORMONES FOR TREATING OR PREVENTING OBESITY AND PUMPS COMPRISING SAID COMPOSITION | Adocia (FR) | 2023-03-08 | — | — | EP | disclosed |
| CN-115181173-A | Preparation method of Tirzepatide | 深圳市健元医药科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-114249808-A | Synthesis method of Cagrilintide | 杭州诺泰澳赛诺医药技术开发有限公司 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | MEN1 1450/4885KMT2A 3707/4885DPP7 70/4885 |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | MEN1 1450/4885KMT2A 3707/4885DPP7 70/4885 |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | MEN1 1450/4885KMT2A 3707/4885DPP7 70/4885 |
| US-20230091653-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | MEN1 1450/4885KMT2A 3707/4885DPP7 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.